ATE147633T1 - Immunhilfsmittel aus liposome enthaltend lymphokin il -2 - Google Patents

Immunhilfsmittel aus liposome enthaltend lymphokin il -2

Info

Publication number
ATE147633T1
ATE147633T1 AT89912751T AT89912751T ATE147633T1 AT E147633 T1 ATE147633 T1 AT E147633T1 AT 89912751 T AT89912751 T AT 89912751T AT 89912751 T AT89912751 T AT 89912751T AT E147633 T1 ATE147633 T1 AT E147633T1
Authority
AT
Austria
Prior art keywords
liposomes containing
lymphokine
immune
aid
containing lymphokine
Prior art date
Application number
AT89912751T
Other languages
English (en)
Inventor
Peter M Anderson
Arnold S Leonard
Augusto C Ochoa
Cynthia Loeffler
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE147633T1 publication Critical patent/ATE147633T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89912751T 1988-10-27 1989-10-25 Immunhilfsmittel aus liposome enthaltend lymphokin il -2 ATE147633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26354688A 1988-10-27 1988-10-27
US38277889A 1989-07-19 1989-07-19

Publications (1)

Publication Number Publication Date
ATE147633T1 true ATE147633T1 (de) 1997-02-15

Family

ID=26949917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912751T ATE147633T1 (de) 1988-10-27 1989-10-25 Immunhilfsmittel aus liposome enthaltend lymphokin il -2

Country Status (7)

Country Link
US (3) US5409698A (de)
EP (1) EP0440742B1 (de)
JP (1) JP2955314B2 (de)
AT (1) ATE147633T1 (de)
AU (1) AU4525589A (de)
DE (1) DE68927679T2 (de)
WO (1) WO1990004412A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
JPH06505701A (ja) * 1990-09-10 1994-06-30 スクール・オブ・フアーマシー・ユニバーシテイ・オブ・ロンドン リポソーム
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
ES2204919T3 (es) * 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
AU7877894A (en) * 1993-09-24 1995-04-10 Maurizio Zanetti Treatment of hiv infection with humic acid
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
US5994318A (en) * 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
CA2178902A1 (en) * 1993-12-14 1995-06-22 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
FR2716373B1 (fr) * 1994-02-23 1996-05-03 Pasteur Institut Liposomes, et leur utilisation pour l'obtention de vaccins.
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0918539B1 (de) * 1996-02-16 2005-10-19 Biomira Usa Inc. Impfstoff gegen tumore der b-lymphozyten
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
CN102580069B (zh) 2003-01-07 2015-09-30 耶达研究及发展有限公司 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
EP1624858B1 (de) 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Neue encochleationsverfahren
EP1631669A2 (de) 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Gegen proteinexpression gerichtete cochleat-zusammensetzungen
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
ES2641375T3 (es) * 2012-11-02 2017-11-08 Cytuvax Composición que comprende macroagregados de citoquinas
EP3049114B1 (de) 2013-09-27 2021-11-10 Massachusetts Institute of Technology Trägerfreie biologisch aktive proteinnanostrukturen
CN108990413A (zh) 2015-08-12 2018-12-11 麻省理工学院 纳米颗粒的细胞表面偶联
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4229441A (en) * 1978-12-01 1980-10-21 Merck & Co., Inc. Immunologic adjuvant
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3175036D1 (en) * 1980-10-02 1986-09-04 Hooper Trading Co Nv A t-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
US4684625A (en) * 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4473495A (en) * 1983-07-28 1984-09-25 Northwestern University Albumin-solubilized hymenoptera venoms for vaccine use
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
BE902089A (fr) * 1984-04-09 1985-10-02 Sandoz Sa Perfectionnements a la therapie par l'interleukine.
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
EP0172007B1 (de) * 1984-08-10 1991-05-22 Syntex (U.S.A.) Inc. Stabile Liposome mit wasserlöslichen Arzneimitteln
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3687014T2 (de) * 1985-05-01 1993-04-01 Asahi Chemical Ind Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
DE3682257D1 (de) * 1985-11-22 1991-12-05 Takeda Chemical Industries Ltd Liposomzusammensetzung.
EP0256119A4 (de) * 1986-02-10 1988-08-23 Liposome Technology Inc Liposomenverabreichungssystem mit geregelter verabreichung.
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
EP0274219A3 (de) * 1986-12-04 1988-08-03 Takeda Chemical Industries, Ltd. Interleukin-2 enthaltende Liposan-Zusammensetzung und Methode zu ihrer Herstellung
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
ATE84221T1 (de) * 1987-12-03 1993-01-15 Liposome Co Inc Arzneimittel mit methylcellulose.
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
JPH03503844A (ja) * 1988-04-15 1991-08-29 リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド Ｌａｋ細胞サイトトキシン
JPH03505576A (ja) * 1988-05-16 1991-12-05 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 有機化合物に関する改良
US4950647A (en) * 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy

Also Published As

Publication number Publication date
EP0440742A1 (de) 1991-08-14
WO1990004412A1 (en) 1990-05-03
US5409698A (en) 1995-04-25
AU4525589A (en) 1990-05-14
DE68927679T2 (de) 1997-06-26
JPH04501562A (ja) 1992-03-19
JP2955314B2 (ja) 1999-10-04
EP0440742B1 (de) 1997-01-15
US5773006A (en) 1998-06-30
DE68927679D1 (de) 1997-02-27
US5650152A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
ATE147633T1 (de) Immunhilfsmittel aus liposome enthaltend lymphokin il -2
DK323486D0 (da) Monoklont antistof mod et med human carcinom associeret antigen
IT1204630B (it) Iniettori di combustibile
NO830551L (no) Fluorkarbon-overflateaktive midler
DK283588D0 (da) Monoklonalt antistof mod ovariecancerceller
IT1185235B (it) Dispositivo di pompaggio di combustibile
AU7921787A (en) Monoclonal antibodies to omega-interferons
IT1177025B (it) Iniettore di combustibile
IT1200674B (it) Dispositivo di pompaggio di combustibile
IT1197838B (it) Perfezionamenti apportati al dosaggio di combustibile ad un motore
IT8722884A0 (it) Composizione di carburante diesel.
AU585279B2 (en) Pesticidal biphenylyloxy and biphenylylalkoxy aryl acyl urea compounds
IT8322403A0 (it) Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato eprocedimento per la preparazione degli stessi.
IT1176374B (it) Inietore di combustibile
IT8521901A0 (it) Combustibile. dispositivo di pompaggio di
IT1210812B (it) Procedimento per la fabbricazione di strati monocristallini di tellururo di cadmio e mercurio
ES526543A0 (es) Perfeccionamientos introducidos en la construccion de bombas impulsoras de combustible
DK480985D0 (da) Antigen peptidforbindelse
SU1064838A1 (ru) Проточный газовый лазер
IT1175951B (it) Iniettore di combustibile
KR890022426U (ko) 배낭의 멜빵 고정장치
NO820808L (no) Vibrasjonsdempet stol.
IT8211570V0 (it) Fibbia per cinture,smontabile e ribaltabile con l'ausilio di un chiavistello elastico
IT8236044V0 (it) Sedile portatile con spalliera
IT8448704A0 (it) Carburatore e compensazione di altitudine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties